Abstract Regenerative endodontics has a compelling biological rationale and encouraging early clinical reports. Yet translation into routine practice still proceeds largely through fragmented case series, heterogeneous protocols, and inconsistent follow-up, all of which make cumulative learning difficult. The central bottleneck is therefore not only whether regeneration can occur, but whether early clinical use is organized to produce interpretable lessons rather than disconnected anecdotes. Using Japan’s regenerative medicine governance framework as an illustrative example, this Commentary argues for supervised translation pathways built around four portable functions: (1) risk-tiered independent review linked to auditable plan registration and amendment tracking; (2) standardized, quality-controlled, and traceable cell procurement and processing; (3) qualified delivery sites operating to defined competency and deviation-reporting standards; and (4) independent outcome capture using harmonized definitions, prespecified follow-up, and periodic oversight. These functions are not a substitute for comparative trials and cannot establish efficacy. However, they can reduce avoidable procedural noise, make protocol drift visible, and support corrective action, turning early clinical use into a more reviewable and learnable phase of translation while stronger evidence is built.
Nakashima et al. (Thu,) studied this question.